- Supported exchanges /
- F /
- 4RD.F
MAAT PHARMA S.A. EO-1 (4RD F) stock market data APIs
MaaT Pharma SA, a clinical stage company, engages in the research and development of microbiome biotherapies for the treatment of solid cancer tumors. Its products pipeline includes MaaT013 that has completed phase 2 clinical trials for the treatment of acute graft versus host diseases, as well as in preclinical trials to treat melanoma; MaaT033, which is in phase 1b clinical trials for the improvement of survival in patients with acute myeloid leukemia or other liquid tumors receiving allogeneic hematopoietic stem cell transplantation; and MaaT03X for the treatment of solid tumors. The company was incorporated in 2014 and is headquartered in Lyon, France.
MAAT PHARMA S.A. EO-1 Financial Data Overview
| 7.04 | |
| 7.22 | |
| - | |
| 7.22 | |
| 6.86 | |
| 5.8-9.92 | |
| 99 455 K | |
| 13 890 K | |
| 2 571 K | |
| 0.2 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
MAAT PHARMA S.A. EO-1 Fundamental Data is available in our Financial Data APIs
- Net Revenue 2 571 K
- EBITDA -23 943 000
- Earnings Per Share -1.7
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get MAAT PHARMA S.A. EO-1 Earnings via APIs
- Latest Release NaN
- EPS/Forecast NaN
Get MAAT PHARMA S.A. EO-1 End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
